Related Experiment Video
Updated: Jul 10, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Routine pharmacogenetic testing in clinical practice: dream or reality?
1GlaxoSmithKline, Pharmacogenetics, Research and Development, 5 Moore Drive, Research Triangle Park, Durham, NC 27709, USA. iris.x.grossman@gsk.com
Pharmacogenomics
|November 6, 2007
Summary
Pharmacogenetics (PGx) research shows promise but current findings are insufficient for routine clinical use. Further validation, standardization, and prospective studies are needed to integrate PGx into healthcare effectively.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Psychiatric Drug Development
Background:
- Pharmacogenetics (PGx) is gaining popularity for personalized medicine.
- Extensive research exists on genetic influences on drug response.
- Limited PGx applications are currently used in routine healthcare.
Purpose of the Study:
- To review PGx research in psychiatric drugs.
- To identify reasons for the lack of clinical implementation.
- To propose steps for validating PGx for clinical use.
Main Methods:
- Literature review focusing on PGx of psychiatric medications.
- Analysis of current limitations in PGx research and application.
- Development of recommendations for future PGx studies and implementation.
Main Results:
- Published PGx findings are currently inadequate for routine clinical prediction of drug safety, efficacy, or dosing.
- Examples from psychiatric drug PGx highlight the insufficiency of current data.
- Key areas for improvement include standardization, technical assay quality, and study design.
Conclusions:
- Demonstrating the validity, utility, and cost-effectiveness of PGx is crucial.
- Standardized criteria and prospective studies are necessary for clinical integration.
- Recommendations aim to facilitate PGx reimbursement and routine clinical practice.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...